Extract:
Based on this comprehensive report published by Gravitas Market Insights, the Monoclonal Antibodies market is said to witness a significant growth during the forecast years between 2021 and 2028. Monoclonal Antibody therapy is an immunotherapy which uses monoclonal antibodies (mAb) to bind mono particularly to proteins or specific cells. Monoclonal antibodies are widely used for the treatment of chronic and severe conditions. One of the primary factors contributing the demand for the growth of monoclonal antibodies market is the high demand for biologics and this is owing to the increasing incidence of cancer and other chronic conditions.
Report Scope in detail:
This latest report edition of Monoclonal Antibodies market has been added to our huge database of detailed reports and this envisions to shape the future of all the related businesses. Our team of learned research analysts have studied in-depth and curated the report based on several aspects which include the overview of the market, driving forces, growth rate, market trends, market size, opportunities and challenges of the market; along with detailed competitive analysis on the regional as well as global level. The Monoclonal Antibodies market research report renders a thorough analysis of the market on a global aspect and aims on several market segmentation. This report also provides deeper perception into the latest trends of the market and pinpoints crucial product developments of the industry. Furthermore, the report collects numerous factors that have accredited to the growth of the market in the recent years.
Monoclonal Antibodies Market Segmentation:
By Type
• Humanized
• Fully human
• Chimeric
• Other Types
By Application
• Infectious diseases
• Autoimmune diseases
• Oncology
• Other Applications
By End-User
• Clinics
• Hospitals
• Other End User
Regional Coverage
• North America
o United States
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Korea
o Australia
o Southeast Asia
o Rest of Asia-Pacific
• South America
o Brazil
o Argentina
o Colombia
o Rest of South America
• Middle East & Africa
o GCC
o South Africa
o Rest of Middle East & Africa
Competitive Analysis:
Eminent market players have been outlined in order to extract improved insights into the worldwide businesses. Our research reports offer all-inclusive information on various top most manufacturers that are operational across global regions. We provide company profiles which include detailed overview of the company, business information, business performance, crucial strategies implemented through the years.
Few of the Key Players Covered in Our Report:
• AbbVie Inc
• F Hoffmann-La Roche Ltd
• Amgen
• Johnson & Johnson
• Bristol Myers Squibb
• Novartis AG
• Merck & Co, Inc.
• AstraZeneca
• GlaxoSmithKline plc
• Eli Lilly and Company
• Takeda Pharmaceuticals
Impact of COVID19:
The COVID19 pandemic crippled the global economy, it resulted in a worldwide lockdown and this has majorly impacted numerous industries. Our industry experts are working round-the-clock to identify, accumulate and in-time deliver market analysis due to the effect of unprecedented decisions in COVID-19 repercussions on many businesses. The full version of this report will comprise the overall impact of the pandemic, and predicted alteration on the future outlook of the industry, by taking into the account the economic, political, technological and social parameters.
Section 1: Executive Summary
1.1. Monoclonal Antibodies Market Industry 360° outline, Year 2016 - 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Applications Trends
1.5. Regional Trends
Section 2: Market Dynamics - Monoclonal Antibodies Market Industry Insights
2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter's Analysis
2.6. Worldwide Industry Landscape, Year 2016 - 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment
Section 3: Global Monoclonal Antibodies Market, By Type
3.1. Segmentation Analysis, By Type, 2016-2028
3.2. Market Share Segmentation Analysis, By Type, 2016-2028
3.3. Humanized
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.4. Fully human
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.5. Chimeric
3.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
3.6. Other Types
3.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 4: Global Monoclonal Antibodies Market, By Applications
4.1. Segmentation Analysis, By Applications, 2016-2028
4.2. Market Share Segmentation Analysis, By Applications, 2016-2028
4.3. Infectious diseases
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
4.4. Autoimmune diseases
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
4.5. Oncology
4.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
4.6. Other Applications
4.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 5: Global Monoclonal Antibodies Market, By End User
5.1. Segmentation Analysis, By End User, 2016-2028
5.2. Market Share Segmentation Analysis, By End User, 2016-2028
5.3. Clinics
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
5.4. Hospitals
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
5.5. Other End User
5.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 6: Global Monoclonal Antibodies Market, Regional Analysis
6.1. Global Monoclonal Antibodies Market, Regional Analysis
6.2. North America, Country level Analysis
6.2.1. North America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Type, 2016 - 2028
6.2.2. North America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Applications, 2016 - 2028
6.2.3. North America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By End User, 2016 - 2028
6.2.4. United States
6.2.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.2.5. Canada
6.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.2.6. Mexico
6.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3. Europe Country level Analysis
6.3.1. Europe Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Type, 2016 - 2028
6.3.2. Europe Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Applications, 2016 - 2028
6.3.3. Europe Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By End User, 2016 - 2028
6.3.4. UK
6.3.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.5. Germany
6.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.6. France
6.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.7. Italy
6.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.8. Spain
6.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.9. Russia
6.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.3.10. Rest of Europe
6.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4. Asia-Pacific Country level Analysis
6.4.1. Asia-Pacific Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Type, 2016 - 2028
6.4.2. Asia-Pacific Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Applications, 2016 - 2028
6.4.3. Asia-Pacific Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By End User, 2016 - 2028
6.4.4. China
6.4.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.5. India
6.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.6. Japan
6.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.7. Korea
6.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.8. Australia
6.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.9. Southeast Asia
6.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.4.10. Rest of Asia-Pacific
6.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.5. South America Country level Analysis
6.5.1. South America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Type, 2016 - 2028
6.5.2. South America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Applications, 2016 - 2028
6.5.3. South America Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By End User, 2016 - 2028
6.5.4. Brazil
6.5.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.5.5. Argentina
6.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.5.6. Colombia
6.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.5.7. Rest of South America
6.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.6. Middle East & Africa Country level Analysis
6.6.1. MEA Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Type, 2016 - 2028
6.6.2. MEA Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By Applications, 2016 - 2028
6.6.3. MEA Monoclonal Antibodies Market estimates and forecast with Growth rate analysis, By End User, 2016 - 2028
6.6.4. GCC
6.6.4.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.6.5. South Africa
6.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
6.6.6. Rest of Middle East & Africa
6.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 - 2028
Section 7: Company Profile - Monoclonal Antibodies Market
7.1. AbbVie Inc
7.1.1. Business Overview
7.1.2. Product & Service Offering
7.1.3. Overall Revenue
7.1.4. Strategic Outlook
7.2. F Hoffmann-La Roche Ltd
7.2.1. Business Overview
7.2.2. Product & Service Offering
7.2.3. Overall Revenue
7.2.4. Strategic Outlook
7.3. Amgen
7.3.1. Business Overview
7.3.2. Product & Service Offering
7.3.3. Overall Revenue
7.3.4. Strategic Outlook
7.4. Johnson & Johnson
7.4.1. Business Overview
7.4.2. Product & Service Offering
7.4.3. Overall Revenue
7.4.4. Strategic Outlook
7.5. Bristol Myers Squibb
7.5.1. Business Overview
7.5.2. Product & Service Offering
7.5.3. Overall Revenue
7.5.4. Strategic Outlook
7.6. Novartis AG
7.6.1. Business Overview
7.6.2. Product & Service Offering
7.6.3. Overall Revenue
7.6.4. Strategic Outlook
7.7. Merck & Co, Inc.
7.7.1. Business Overview
7.7.2. Product & Service Offering
7.7.3. Overall Revenue
7.7.4. Strategic Outlook
7.8. AstraZeneca
7.8.1. Business Overview
7.8.2. Product & Service Offering
7.8.3. Overall Revenue
7.8.4. Strategic Outlook
7.9. GlaxoSmithKline plc
7.9.1. Business Overview
7.9.2. Product & Service Offering
7.9.3. Overall Revenue
7.9.4. Strategic Outlook
7.10. Eli Lilly and Company
7.10.1. Business Overview
7.10.2. Product & Service Offering
7.10.3. Overall Revenue
7.10.4. Strategic Outlook
7.11. Takeda Pharmaceuticals
7.11.1. Business Overview
7.11.2. Product & Service Offering
7.11.3. Overall Revenue
7.11.4. Strategic Outlook
*Market size and forecast will be provided from 2016-2028, and forecast period would be 2021-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis
Request Sample 
Request Discount 
Inquire Before Buy
